Story preview
An estimated $216M Q3 expense lowers AbbVie (ABBV)'s 2026 adjusted earnings outlook.
About this story
- Published
- Oct 5, 2026, 8:08 PM UTC
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →Stock Titan
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee